Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Liminal BioSciences Inc. LMNL

Liminal BioSciences is a biopharmaceutical company focused on the discovery and development of novel, small molecule drug candidates for the treatment of patients suffering from fibrotic or inflammatory diseases that have a high unmet medical need. Liminal BioSciences operates on an integrated basis from our talent hubs in Laval, Quebec, Canada, and Cambridge, UK. Our common shares are listed for trading on the Nasdaq Global Market.


NDAQ:LMNL - Post by User

Comment by stockbuphoonon Jun 11, 2021 9:07am
62 Views
Post# 33371116

RE:and this is the scammer plitheone replying to himself

RE:and this is the scammer plitheone replying to himself

Realstocky/ Newcamo (same guy behind both boardnames), you're the only one brain dead enough not to realize that he was making fun of you using your 2 boardnames for years to support your 3 vague pumps with no explanation of how this company will be successful with no IPF and no Ryplazim. Piper downgraded when LMNL management was stupid enough to report that IPF failed the grade in the middle of a Phase 1 trial. They received a Complete Review Letter and didn't report that material news for a year so why the rush to report IPF fail that triggered a response by a good analyst to update their price target - 
from $22 to $4.50 since her report was based on 4050 / IPF. And you dismiss it because you have not read the old report or the updated report. Now, that is a dumb pumper. 

realstocky wrote:

this guys has several accounts, sometime forgets to switch, funny and sad at same time:) =>

PLITheOne (403)
April 09, 2021 - 10:50 AM
27 Reads
Post# 32966313

PliTheOne

I agree with PliTheOne! He seems to have knowledgable insight of the unethical behaviour of Thomvest and where this turd is headed. Not too much longer for this chart to look like a double black diamond ski hill. Hold on, it's coming!


 



<< Previous
Bullboard Posts
Next >>